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Invasive aspergillosis has been mainly reported among
immunocompromised patients during prolonged
periods of neutropenia. Recently, however,
non-neutropenic patients in the ICU population have
shown an increasing risk profile for aspergillosis.
Associations with chronic obstructive pulmonary
disease and corticosteroid therapy have been
frequently documented in this cohort. Difficulties
in achieving a timely diagnosis of aspergillosis in
non-neutropenic patients is related to the
non-specificity of symptoms and to lower yields with
microbiological tests compared to neutropenic
patients. Since high mortality rates are typical of
invasive aspergillosis in critically ill patients, a high
level of suspicion and prompt initiation of adequate
antifungal treatment are mandatory. Epidemiology,
risk factors, diagnostic algorithms, and different
approaches in antifungal therapy for invasive
aspergillosis in non-neutropenic patients are reviewed.A better understanding of the population at risk and theReview
Introduction
Invasive aspergillosis (IA) is an opportunistic infection
that occurs mainly among patients with hematological
malignancies, most notably during prolonged periods of
neutropenia, but also in subjects with solid tumors,
critical illness, and HIV/AIDS, and those undergoing
allogeneic stem cell transplantation and solid-organ
transplantation [1,2]. In recent years, however, IA has
increasingly been recognized as an emerging disease of
non-neutropenic patients and in patients admitted to
the ICU, even in the absence of an apparent predispos-
ing immunodeficiency [3-8]. Although not uncommon,* Correspondence: mattba@tin.it
1Infectious Diseases Division, Santa Maria Misericordia University Hospital,
33100 Udine, Italy
Full list of author information is available at the end of the article
© 2014 Bassetti et al.; licensee BioMed Central
for 12 months following its publication. After
Attribution License (http://creativecommons.o
in any medium, provided the original work i
(http://creativecommons.org/publicdomain/the features of IA among immunocompetent patients
differ greatly from those of IA in neutropenic patients.
The epidemiology, clinical characteristics, outcomes, and
prognosis are not well known in immunocompetent pa-
tients. In the ICU, the incidence of IA ranges from 0.3%
to 5.8% [4,5] with an overall mortality rate exceeding
80% [9].
Several recent case series and single-center cohort
reports have documented the expansion of patient popu-
lations at risk for IA that are different from the trad-
itionally recognized risk groups. They include patients
with chronic obstructive pulmonary disease (COPD) and
other chronic lung or connective tissue diseases requiring
corticosteroid therapy, decompensated liver cirrhosis, and
solid cancer with or without treatment [10,11].
The diagnosis of IA in non-neutropenic critically ill
patients is difficult because signs and symptoms are
non-specific, and the initiation of additional diagnostic
examinations is often delayed because of a low clinical
suspicion. A high level of suspicion is needed to obtain
an early diagnosis and a timely therapeutic intervention.
spectrum of diseases caused by IA in non-neutropenic
patients may help to improve the outcome of this poten-
tially treatable disease.
In this review, we describe the epidemiology of and
the risk factors for pulmonary IA in non-neutropenic
patients, limitations and advances in the diagnostic
process, and the different approaches in antifungal ther-
apy, including the main pharmacological properties of
different antifungal drugs.Epidemiology
Despite a documented increase in the incidence of IA in
ICUs, different rates are reported among subsets of ICU
patients. Indeed, a high prevalence (17%) of IA has been
observed in a cohort of 67 patients with severe hospital-
acquired pneumonia admitted to the ICU [12]. AmongLtd. The licensee has exclusive rights to distribute this article, in any medium,
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rg/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
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9 (23%) developed IA 3 days after ICU admission [13].
Retrospective, autopsy-controlled studies showed in-
teresting results. Roosen and colleagues [14] studied
causes of death in the ICU, revealing 15 cases of IA, 5 of
which were undiagnosed before death, among 100 aut-
opsies. In a retrospective study, 127 patients out of 1,850
admissions (6.9%) had microbiological or histopatho-
logical evidence of Aspergillus during their ICU stay [5].
Postmortem examination was done in 47 out of 71 pa-
tients, and 27 (59%) were identified with IA.
In a study comparing neutropenic and non-neutropenic
patients with an IA diagnosis during a 6-year period,
Cornillet and colleagues [6] found a mean number of 15
IA cases per year; of these, approximately half were in the
ICU. In an Italian study conducted in two mixed ICUs
during 2 years, the incidence of IA was 0.2%, much lower
than in other reports from similar ICUs [15].
Risk factors for IA in non-neutropenic patients admit-
ted to the ICU include prolonged treatment with corti-
costeroids before admission, COPD, liver cirrhosis with
prolonged ICU stay (>7 days), solid organ cancer, HIV
infection, and lung transplantation [16]. However, most
of these factors are frequent among non-neutropenic
critically ill patients. An intriguing hypothesis on the
cause of immunosuppression in the apparently immuno-
competent patient with multiple-organ dysfunction re-
lates to the biphasic response to sepsis. Indeed, the
initial hyperinflammatory phase is followed by relative
immunoparalysis. This latter process is characterized by
neutrophil deactivation, and it may put the patient at
risk of developing opportunistic infections, such as IA
[17].
Risk factors
One of the most important risk factors for IA in non-
neutropenic patients is COPD [7]. Patients with COPD
are susceptible to Aspergillus colonization of the lower
tract of the respiratory airway and under particular cir-
cumstances this may lead to invasive infection [18].
COPD patients present alterations in lung structure, an
impaired immunologic response, reduced mucociliary
clearance and mucosal lesions. Moreover, they are prone
to frequent hospitalization, broad-spectrum antibiotic
treatment and invasive procedures. All these factors
could explain the high incidence of aspergillosis in
COPD [7]. Of note, they are frequently treated with cor-
ticosteroids and both inhaled and systemic therapy have
been described as another important risk factor for as-
pergillosis [19,20]. Steroids are able to accelerate the
in vitro growth of Aspergillus spp. since both the innate
and acquired immune responses are impaired [21]. Van-
dewoude and colleagues [22] defined a total daily dose
≥20 mg prednisone or equivalent among criteria fordefining cases of IA. Both compensated and decompen-
sated cirrhosis have been described as risk factors for IA
and impaired phagocytosis has been proposed as a pos-
sible explanation in these groups [23,24]. Diabetes has
been observed as another risk factor [22]. Impaired in-
nate and acquired immunity caused by hyperglycemia
may explain this observation [25]. Several authors report
alcoholism and malnutrition as other possible risk fac-
tors for IA [22,26].
Patients in the ICU are subjected to several therapies
(for example, broad spectrum antibiotics, mechanical
ventilation) and/or maneuvers (for example, insertion of
central venous catheter), which may affect the immune
system defenses. Even though some of these conditions
have been described as possible contributors, additional
factors may be required for the development of IA
[5,16,26].
Immunosuppression has been described as a late stage
of the biphasic response to sepsis and multiple organ
failure syndrome [27]. Hartemink and colleagues [17]
first proposed the association between this condition
and IA development. This could be one of the main rea-
sons why aspergillosis is frequent among patients not
considered immunocompromised by classic criteria.
Clinical diagnosis and case definition
Clinical manifestations of IA (for example, fever, cough,
purulent sputum) may be initially indistinguishable from
those of bacterial bronchopneumonia [28]. The recovery
of the same Aspergillus species from several respiratory
samples in the course of antibiotic-resistant pneumonia
in patients with risk factors is clearly evocative of the
diagnosis [10]. Therefore, it has been proposed that the
isolation of an Aspergillus species from the respiratory
tract in critically ill patients with risk factors (COPD
after corticosteroid exposure, severe underlying disease)
and clinical features of pneumonia should indicate a
probable IA case.
The presence of a persistent pulmonary infection des-
pite broad-spectrum antibiotics or abnormal thoracic
imaging by CT scanning together with one of the risk
factors should trigger further diagnostic exploration
through collection of respiratory secretions and/or la-
boratory markers. Invasive infections in patients with
negative cultures might be supported by positive mo-
lecular and serological tests, such as Aspergillus PCR
and galactomannan (GM) antigen, which requires at
least two sequentially positive samples. Radiological find-
ings can be non-specific in non-neutropenic patients,
and of the typical imaging findings observed in neutro-
penic patients, the air crescent sign was seen in only a
small proportion of cases, while the halo sign was very
rarely observed. The halo sign and air crescent sign in
thoracic CT scans have a high sensitivity (80%) and
Table 1 Clinical algorithm for the diagnosis of invasive
aspergillosis in non-neutropenic patients
Proven invasive pulmonary aspergillosis
● Follow EORTC/MSG criteria
Putative invasive pulmonary aspergillosis (all four criteria must be met)
● 1. Aspergillus-positive lower respiratory tract specimen culture
● 2. Compatible signs and symptoms (one of the following)
Fever refractory to at least 3 days of appropriate antibiotic
therapy
Recrudescent fever after a period of defervescence of at least
48 hours while still on antibiotics and without other apparent
cause
Pleuritic chest pain
Pleuritic rub
Dyspnea
Hemoptysis
Worsening respiratory insufficiency in spite of appropriate
antibiotic therapy and ventilatory support
● 3. Abnormal medical imaging by portable chest X-ray or CT
scan of the lungs
● 4. Either 4a or 4b
4a. Host risk factors (one of the following conditions)
Neutropenia preceding or at the time of ICU admission
Underlying hematological or oncological malignancy
treated with cytotoxic agents
Glucocorticoid treatment (prednisone equivalent,
20 mg/day)
Congenital or acquired immunodeficiency
COPD, decompensated cirrhosis
4b. Semiquantitative Aspergillus-positive culture of BAL fluid
without bacterial growth together with a positive
cytological smear showing branching hyphae
Aspergillus respiratory tract colonization
● When >1 criterion necessary for a diagnosis of putative IPA is not
met, the case is classified as Aspergillus colonization
BAL, bronchoalveolar lavage; COPD, chronic obstructive pulmonary disease;
CT, computed tomography; EORTC/MSG, European Organization for Research
and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and
the National Institute of Allergy and Infectious Diseases Mycoses Study Group;
IPA, invasive pulmonary aspergillosis.
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with pulmonary infection [29]. In non-neutropenic
patients, a lower sensitivity (5 to 24%) is reported in the
literature and these signs are less frequently observed
[30,31]. Bronchoscopy manifestations were also non-
specific in non-neutropenic patients, with a lack of con-
sistent endoscopic features [31].
The diagnosis of IA is particularly problematic. Ac-
cording to the revised definitions for invasive fungal dis-
ease of the European Organization for Research and
Treatment of Cancer/Invasive Fungal Infections Co-
operative Group and the National Institute of Allergy
and Infectious Diseases Mycoses Study Group (EORTC/
MSG) Consensus Group, IA is categorized into proven,
probable, and possible invasive fungal disease [32].
These diagnostic criteria have proven to be useful in re-
search and practice in severely immunocompromised
patients. The lack of specific criteria for diagnosing IA
in non-neutropenic patients, however, hampers the
timely initiation of appropriate antifungal therapy and
may, as such, compromise the odds of survival. Recently,
Blot and colleagues [33] externally validated a clinical
diagnostic algorithm (Table 1) that aims to discriminate
colonization from probable IA in ICU patients with As-
pergillus-positive endotracheal aspirate cultures.
Microbiological diagnosis
The microbiological diagnosis of aspergillosis can be
achieved using conventional and molecular approaches,
including antigen detection and PCR assays [34,35]. The
direct examination of clinical specimens by microscopy
is particularly relevant to observe the fungal parasitism;
this morphology can allow a presumptive diagnosis of
aspergillosis. Microscopy is generally performed using
wet preparations (potassium hydroxide, calcofluor) and
Wright or Giemsa stains. Other specialized stains, like
periodic acid-Schiff or Gomori methenamine silver, are
generally performed in the histology laboratory [34].
Since Aspergillus microscopic fungal elements can be
confused with those of Fusarium and Scedosporium spe-
cies, conventional culture methods are essential for iso-
lating and identifying the etiological agent. Identification
is largely based on an accurate analysis of the macro-
and microscopic features of the colonies: the size, color
and shape of the colony, microscopic visualization of co-
nidiophores and conidial heads, morphology size and
color of the conidia are important features useful to
identify the isolate at the species level [34,36]. More re-
cently, DNA sequencing and the matrix-assisted laser
desorption/ionization-time of flight mass spectrometry
proteomic approach have proven to be useful tools to
identify non-sporulating isolates or isolates with atypical
morphology [37,38]. It should be remembered that a
negative result by both microscopy and culture does notexclude an active infection. The availability of clinical
Aspergillus spp. isolates allows in vitro antifungal suscep-
tibility testing, which can be useful to detect the emer-
gence of resistance, especially to triazoles [39].
The detection of antibodies against Aspergillus is
strongly dependent on the immune status of the patient
and has been proven to be of little value in the diagnosis
of IA [35].
The Platelia Aspergillus enzyme immunoassay (Bio-
Rad Laboratories, Redmond, WA, USA) reveals the
presence of GM, a polysaccharide of the outer cell wall
layer of Aspergillus, in patients with suspected aspergil-
losis [34,35]. Because GM is produced at the apical
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of this immunoassay decreases when antifungal therapy
is successful [34]. GM can be detected in body fluids,
but serum levels in non-neutropenic patients do not
seem to be accurate because circulating neutrophils are
able to clear the antigen. Meersseman and colleagues
[40] demonstrated a high sensitivity and specificity of
GM in bronchoalveolar lavage (BAL) for the diagnosis of
IA; the sensitivity of BAL GM was 88% compared with
40% for serum GM. GM detection in BAL is, therefore,
a valuable tool for the diagnosis of IA also in non-
neutropenic patients. Alternatively, we could test for
1,3-β-D-glucan, a cell-wall component of many fungi, in
sera of patients with suspected aspergillosis.
Encouraging results have been obtained using PCR
techniques (that is, real time, nested) to detect Aspergil-
lus DNA in the sera of patients with proven and prob-
able aspergillosis. Although these tests have the
advantage of being non-invasive and EU approved real
time PCR kits could overcome the problems related to
the absence of a standardized methodology, molecular
detection of nucleic acids is not yet considered suffi-
ciently reliable for use in the diagnosis of IA [32,41].
Moreover, conflicting results have been described in
cases of histologically proven invasive aspergillosis when
the PCR method was performed on BAL [42,43].
Therapeutic approaches
Prompt administration of appropriate antifungal therap-
ies for IA are immensely important to limit its mortality
rate, which ranges from 60% to 90% [16]. Hence, even
patients without classic risk factors (that is, COPD, ste-
roids and immunosuppressive agent use, hepatic failure,
ICU-related immunoparalysis) should start adequate an-
tifungal therapy upon suspicion of IA before obtaining
definitive proof of infection. Early treatment initiation
according to first-line therapy, at the stage of possible in-
fection, has been reported to be associated with im-
proved outcome in a retrospective cohort of 289 IA
cases characterized by different predictors of death [44].
Additionally, with the exclusion of neutropenic and
allogenic hematopoietic stem cell transplantation recipi-
ents, the usefulness of anti-fungal prophylaxis has not
been established. In non-neutropenic critically ill pa-
tients admitted to the ICU, this preventive approach is
thus not recommended [45].
Unlike the setting of febrile neutropenic episodes,
there is no consensus about the exact time frame to use
before starting empirical therapy without any diagnostic
support in other critically ill patients at risk of IA [46].
In a 6-year French survey, non-neutropenic patients
with IA were less likely to show symptoms; nevertheless,
microbiological samples, antigenemia assays and thor-
acic CT findings had sensitivities similar to those ofneutropenic patients [6]. In non-neutropenic patients,
therefore, a pre-emptive approach based on microbio-
logical biomarkers (GM, Aspergillus PCR, 1,3-beta-glucan)
may be useful and should be implemented for early detec-
tion and prompt treatment of invasive fungal infections in
the ICU [11,47].
Three classes of antifungal agents are available for the
treatment of IA: azoles (voriconazole, posaconazole, itra-
conazole), amphotericin B, and echinocandins (Table 2).
Current guidelines recommend voriconazole as first-line
treatment for IA, including severely critically ill patients,
where intravenous administration is preferred [48]. Dur-
ing the past 10 years, voriconazole use has been widely
and progressively used. In a randomized controlled trial
in 2002 involving 277 patients with IA mainly affected
by hematologic diseases, voriconazole use compared
with amphotericin B was associated with statistically sig-
nificant higher successful outcomes, survival rates and
fewer severe adverse events [49]. Voriconazole was the
main antifungal used for the treatment of IA during a
large prospective surveillance study conducted in North
America between 2004 and 2008 [50]. In a retrospective
study of 289 IA patients, the authors observed that, after
October 2002 (when amphotericin B formulations where
replaced by voriconazole as the first-line anti-Aspergillus
treatment), the overall survival rate increased from
47.5% to 60.4% (P = 0.01), without concomitant modifi-
cations regarding diagnostic strategy [44]. Recently, Bur-
ghi and colleagues [51] analyzed data from 67 patients
admitted to ICU with acute respiratory failure due to in-
fection with Aspergillus spp. Voriconazole therapy was
independently associated with lower mortality, confirm-
ing its primary role in the management of IA. A large
retrospective cohort study investigating risk factors and
outcome of ICU patients with IA (excluding those with
classic risk factors) showed that a 1-day delay in starting
effective antifungal therapy was associated with a longer
length of stay (by 1.28 days) and 4% higher total costs
per day (P < 0.001). Voriconazole was the most fre-
quently prescribed antifungal and its use appeared to
improve the abovementioned outcome measures [52].
Data collected from a large multinational randomized
controlled trial, involving mainly hematological and
transplanted patients, confirmed better outcomes for pa-
tients treated with voriconazole compared with conven-
tional amphotericin B, even though total treatment costs
were similar [53].
Itraconazole is considered a second-line therapeutic
agent for the treatment of IA, especially in severely ill
patients. However, its oral use has been described in
non-life-threatening infections where the patients
had already been stabilized with a more potent agent
[54]. Posaconazole is a broad-spectrum triazole with
anti-Aspergillus activity similar to that of voriconazole.
Table 2 Treatment of invasive aspergillosis in non-neutropenic ICU patients [48]
Setting First choice Alternatives
Primary
therapy
Voriconazole (6 mg/kg every 12 hours intravenously on day 1, then
4 mg/kg every 12 hours intravenously)
Liposomial amphotericin B (3–5 mg/kg/day intravenously) or
Echinocandins (usual dosage)
Salvage
therapy
Combination of voriconazole plus amphotericin B/echinocandins
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tients with IA and other mycoses, its use was associated
with a 42% survival rate [48]. However, limited clinical
experience with it and the absence of intravenous for-
mulations strongly reduce its applicability in critically ill
patients. Although rare, triazole resistance in Aspergillus
spp. (that is, Aspergillus fumigatus) has been reported.
In these cases, alternative antifungal treatment should
be adopted [55].
Before the introduction of voriconazole, amphotericin
B was the main treatment for IA. The deoxycholate for-
mulation was associated with severe nephrotoxicity,
infusion-related adverse events (fever, chills, arthralgias),
and poor outcomes. Three lipid formulations have been
approved and are associated with fewer renal toxicity
and drug-related side effects, although optimal dosages
have not been defined for any of these compounds [56].
In a population of 201 patients with confirmed IA,
Cornely and colleagues [57] demonstrated that patients
who received a high dose of liposomal amphotericin
B (10 mg/kg/day) did not experience higher cure rates
compared with standard doses, although relevant
nephrotoxicity was observed. In a retrospective cohort
of 16 COPD patients with IA treated with a deoxycho-
late formulation, the mortality rate was 100%, mainly
due to septic shock or multiorgan failure. This poor
prognosis raised doubts about the need for higher doses
or lipid formulations in specific subgroups of patients
[3].
All echinocandins have been shown to have in vitro
and in vivo activity against Aspergillus spp. However,
only caspofungin is approved for the treatment of IA in
patients who are intolerant to first-line compounds
[48]. In two phase II studies involving leukemic and
hematopoietic stem cell transplantation patients treated
with caspofungin, 12-week survival exceeded 50% [58].
Although still not approved, two other echinocandins
(anidulafungin and micafungin) are used in clinical prac-
tice, especially with non-neutropenic patients. In break-
through IA and refractory diseases, combination therapy
(for example, echinocandin plus voriconazole or liposo-
mal amphotericin B) may be considered.
Although limited by the use of historical controls,
some studies suggest the benefits of voriconazole-
caspofungin combinations [59,60]. Furthermore, in a
subgroup of 40 solid organ transplant recipients, this
combination, as first-line therapy, was associated withsignificantly reduced mortality compared with ampho-
tericin B [61]. Similarly, a caspofungin-amphotericin B
combination has been used with a more than 50%
favorable antifungal response [62,63]. On the other hand,
no clinical data support triazole-amphotericin B combi-
nations due to possible antagonistic interactions. A
phase III clinical trial investigating the effectiveness of a
voriconazole-anidulafungin combination did not provide
conclusive results [64]. All-cause mortality rates at week
6 for proven or probable IA cases was 19.3% in the
voriconazole-anidulafungin group versus 27.5% in the
voriconazole group. A recent meta-analysis on combin-
ation therapy for IA concluded that the available clinical
evidence is not conclusive and of moderate strength
[65].
The optimal duration of IA treatment is not known.
Early assessment of treatment response is essential to con-
firm effectiveness. The site of infection, immunosuppres-
sive status, baseline clinical conditions and subsequent
therapeutic interventions may all influence physicians’
decisions. Generally, antifungals are not interrupted until
all clinical signs have disappeared and radiological abnor-
malities have stabilized.
Recommendations regarding management of IA in
non-neutropenic patients principally derive from evi-
dence from hematological population studies. Large ob-
servational cohort studies and interventional trials are
needed in order to define the most appropriate thera-
peutic approaches in non-neutropenic critically ill ICU
patients.
Pharmacological properties of voriconazole
One of the main pharmacokinetic parameters of vorico-
nazole is its excellent oral bioavailability [66-68]. It pos-
sesses the highest bioavailability among triazoles (>85 to
90%), which results in rapidly high plasma concentra-
tions. The absorption of voriconazole is not affected by
gastric pH but is decreased by co-administration with
food [69]. Peak plasma concentrations close to steady
state are rapidly achieved via an intravenous loading
dose followed by a maintenance dose within the
first 24 hours of administration, but only after 5 to 7 days
following multiple oral administrations. Thus, the intra-
venous route seems to be preferable for initial adminis-
tration of voriconazole in critically ill patients suffering
from IA in order to achieve therapeutic voriconazole
levels as early as possible.
Table 3 Standard dosing in adults and children
Adults and adolescents (>12 years and >50 kg)
Loading dose, for the first 24 hours
● IV: 6 mg/kg every 12 hours
● Oral >40 kg: 400 mg every 12 hours
● Oral <40 kg: 200 mg every 12 hours
Maintenance dose
● IV: 4 mg/kg every 12 hours
● Oral >40 kg: 200 mg every 12 hours
● Oral <40 kg: 100 mg every 12 hours
IV, intravenous.
Bassetti et al. Critical Care 2014, 18:458 Page 6 of 12
http://ccforum.com/content/18/1/458An analysis of pharmacokinetic data from several vori-
conazole clinical trials showed that median voriconazole
plasma concentrations in older patients (>65 years) were
approximately 80% to 90% higher than those in youn-
ger patients after both intravenous and oral administra-
tion [70]. The estimated voriconazole oral bioavailability
was lower (60%) than previously observed, which might
be explained by altered gastrointestinal function, which is
frequent in onco-hematological patients [70]. Voriconazole
is mainly eliminated by the liver, while kidney elimination
is negligible, and less than 5% of the active drug is found
in urine.
Voriconazole achieves therapeutically effective concen-
trations in the epithelial lining fluid after standard doses
[71-73]. A recent experience assessing trough voricona-
zole concentrations in plasma and pulmonary epithelial
lining fluid of lung transplant recipients receiving oral
voriconazole showed a very high mean ± standard devi-
ation epithelial lining fluid/plasma ratio [74]. This may
by predictive of its efficacy in the treatment of pulmon-
ary aspergillosis. Additionally, voriconazole is extensively
transported across the blood–brain and blood-eye bar-
riers [73,75,76]. A recent reference laboratory experience
of clinically achievable voriconazole concentrations
within cerebrospinal fluid (CSF) showed that, among
173 samples, the median quantifiable CSF level was
2.47 mg/L [77]. The effective levels in CSF may support
the results of a recent retrospective analysis assessing
the efficacy of voriconazole in the treatment of 192 fun-
gal central nervous system infections that documented a
success rate of 48% [78].
Variability of voriconazole serum concentrations is
mainly due to metabolism via the CYP2C19 P450 en-
zyme [79-81]. Standard dosing in adults is outlined in
Table 3.
If a response to voriconazole is inadequate, the main-
tenance oral dose may be increased to 300 mg every
12 hours for patients weighing over 40 kg and to 150 mg
every 12 hours for those <40 kg. Dose adjustment is re-
quired in case of hepatic failure. According to the pre-
scribing information summary, dose adjustments are
required for patients with mild to moderate hepatic dys-
function (Child-Pugh class A and B). The standard load-
ing dose should be provided to these patients, but
maintenance doses should be reduced by 50%. Studies
have not adequately evaluated the safety of voriconazole
in severe liver disease (Child-Pugh class C) [82]. Caution
should be exercised when administering the intravenous
formulation to critically ill patients with renal dysfunc-
tion due to the presence of the solubilizing excipient
sulfobutylether-beta-cyclodextrin. Indeed, two recent
clinical experiences assessing the safety of intravenous
voriconazole in patients with compromised renal func-
tion showed that the route of administration andbaseline renal function were not predictors of worsening
renal dysfunction [83,84].
Although voriconazole has many drug interactions,
their clinical management can be relatively simple
(Table 4) [85].
As far as voriconazole dosing in special populations is
concerned, supratherapeutic concentrations (4 mg/kg
actual body weight) have recently been documented as a
risk [86]. Therefore, dosing voriconazole based on an
ideal body weight or adjusted body weight has been rec-
ommended for morbidly obese patients [86,87]. Con-
versely, clearance of voriconazole during continuous
veno-venous hemofiltration (CVVH) was not clinically
significant, so voriconazole dose adjustment in critically
ill patients undergoing the standard method of CVVH is
not required [88].
Several recent papers have underlined the crucial role
of adequate plasma levels for maintaining efficacy during
treatment of invasive fungal infections in immunocom-
promised patients [87,89-91]. A trough concentration of
at least 1 mg/L was associated with an approximately
70% response rate in adult patients, and to date the rec-
ommended range is between 1 and 5.5 mg/L [70]. Inter-
estingly, a reference laboratory experience of clinically
achievable voriconazole bloodstream concentrations in a
large number of subjects (n = 14,370) showed that
50.6% of samples were within the recommended
trough range [77].
Although we still await definitive evidence-based
guidelines on therapeutic drug monitoring of voricona-
zole, some practical indications, listed in order of im-
portance, are summarized in Table 5.
Pharmacological properties of echinocandins
The echinocandins are semisynthetic lipopeptides that
act as noncompetitive inhibitors of 1,3-beta-D-glucan
synthase, an enzyme complex within the fungal cell wall
[92]. All the echinocandins exert in vitro and in vivo ac-
tivity against Aspergillus spp. [93].
From a pharmacokinetic standpoint, the echinocan-
dins are all similar for some aspects but differ for others
Table 4 The main drugs interacting with voriconazole
Drug Interaction with voriconazole and management strategy
Drugs contraindicated
Astemizole, cisapride, ergot alkaloids, quinidine, sirolimus, terfenadine Their levels are increased by voriconazole, avoid co-administration. Switch
to a drug with no or with predictable interactions (for example,
cyclosporine)
Carbamazepine, long-acting barbiturates, rifampicin They decrease voriconazole levels, avoid co-administration. Switch to a
drug with no interactions (for example, levetiracetam)
Rifabutin Co-administration decreases voriconazole levels and increases rifabutin
levels (contraindicated according to FDA, not according to EMA, see
below), avoid co-administration
Drugs not contraindicated but if co-administered the dose of
voriconazole must be modified (increased)
Phenytoin Increase voriconazole oral maintenance dose from 200 mg to 400 mg
every 12 hours (100–200 mg every 12 hours if <40 kg) and intravenous
maintenance dose to 5 mg/kg every 12 hours; monitor for phenytoin
toxicity
Efavirenz Increase voriconazole oral maintenance dose from 200 mg to 400 mg
every 12 hours (100–200 mg every 12 hours if <40 kg) and reduce
efavirenz dose by 50% to 300 mg/day
Rifabutin (according to FDA contraindicated as rifampicin) According to EMA, increase oral voriconazole maintenance dose from 200
to 350 mg every 12 hours (100–200 mg every 12 hours if <40 kg) and
intravenous maintenance dose to 5 mg/kg every 12 hours; monitor for
rifabutin toxicity
Other drugs (apart from ritonavir, their levels are increased by
voriconazole)
Low dose ritonavir (100 mg every 12 hours) Co-administration decreases levels of both voriconazole and ritonavir;
better avoided
Cyclosporine, omeprazole, tacrolimus and warfarin Their blood levels are increased by voriconazole and their dose should be
reduced (by half for cyclosporine and by two-thirds for tacrolimus).
Monitor serum levels of cyclosporine and tacrolimus or INR for warfarin
Other drugs such as benzodiazepines, opioid analgesics (for example,
oxycodone or fentanyl), sulfonylureas, statins, vinca alkaloids, calcium
channel blockers
Their levels are increased by voriconazole co-administration. Monitor
closely for their side effects, discontinue if toxicity is suspected or
consider decreasing dosage immediately when voriconazole is started
EMA, European Medicines Agency; FDA, Food and Drug Administration; INR, international normalized ratio.
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fuse through the blood–brain barrier and/or the blood-
ocular barrier, have a low propensity for drug-drug phar-
macokinetic interaction (especially anidulafungin), are
not renally cleared and have elimination half-lives longTable 5 Practical indications, listed in order of importance,
when therapeutic drug monitoring of voriconazole might
be useful
Clinical situation
● Suspected treatment failure
● Suspected suboptimal dosing - for example, due to interaction
with other drugs such as phenytoin, in children or in cerebral
infectionsChange in the administration of the drug from intravenous
to oral routea
● Suspected suboptimal absorption
● Suspected non-compliance
● Suspected neurologic toxicity possibly related to overdosing
● Suspected other toxicity possibly related to overdosing
aAs long as the patient is critical, intravenous therapy is preferred in order to
avoid problems with absorption.enough to allow once-daily administration. Recent studies
suggest that the influence of continuous renal replacement
therapy on anidulafungin, caspofungin or micafungin
elimination in critically ill patients appears to be negli-
gible, and that no dosage adjustments are needed for the
echinocandins in patients undergoing CVVH ) [94-98].
It has been shown that hypoalbuminemic post-surgical
patients might experience caspofungin underexposure
due to increased clearance as a result of decreased
plasma protein binding [99]. Likewise, a recent study in
critically ill patients suggested that standard doses of
anidulafungin resulted in lower exposure than in the
general patient population, even if no correlation be-
tween anidulafungin exposure and plasma protein con-
centrations was established [99]. Additionally, it has
been shown that dose optimization of caspofungin in
obese patients may improve clinical success rates [100].
Although these issues are not expected to greatly
affect echinocandin efficacy against Candida strains
[101], they might become more relevant in the presence
of less susceptible pathogens.
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management of proven or probable IA at the standard
dose of 50 mg once daily, it is worth noting that cur-
rently ongoing pharmacokinetic studies in patients with
IA with higher doses ranging between 70 and 200 mg
once daily suggest linear pharmacokinetics with no un-
predictable accumulation across the investigated dosage
range and good safety [102,103].
Pharmacological properties of liposomal amphotericin B
Amphotericin B is a polyene antibiotic that binds to the
ergosterol present in the fungal membrane. Among the
various lipidic formulations of amphotericin B, liposomal
amphotericin B (LAmB) has the more favorable pharma-
cokinetic behavior in terms of achieving higher peak
plasma levels, having lower intracellular penetration
rates and lower clearance through the reticuloendothe-
lial system [104]. Interestingly, both LAmB and ampho-
tericin B lipid complex (ABLC) were shown to achieve
therapeutically effective concentrations in the epithelial
lining fluid of critically ill patients [105]. However, ex-
perimental animal models suggest that only LAmB may
achieve adequate levels in the CSF [106] and the eye
[107].
The pharmacokinetic-pharmacodynamic relationships
of the two most widely used lipid formulations of
amphotericin B (LAmB and ABLC) were shown to differ
markedly in an in vitro lung model of IA, considering
that the concentrations producing a 50% maximal effect
were about four-fold lower for LAmB than for ABLC
[108].
As far as LAmB dosing is concerned, it has been
shown that dosages up to 10 mg/kg/daily gave no benefit
for treatment of IA in comparison with the standard
dose of 3 to 5 mg/kg/daily [57,109]. However it is worth
noting that alternative dosing schedules based on higher
dosages at longer dosing intervals are currently under
evaluation for both prophylactic [110] and therapeutic
[111] purposes.
Although potentially nephrotoxic, LAmB does not
need dosage adjustment in the presence of renal insuffi-
ciency and recent clinical experience suggests that the
impact of LAmB on the renal function of critically ill
patients with impaired renal function was minimal
[112,113].
Outcome and prognostic factors
Only a few clinical studies have investigated the outcome
of IA in critically ill patients. Different studies are diffi-
cult to compare due to the absence of specific clinical
signs, different diagnostic criteria and different coexist-
ing diseases recognized as risk factors [16].
Mortality rates for patients with proven or probable IA
in the ICU range from 59% to 95% and seem to behigher in non-neutropenic patients [114]. A mortality
rate of 60% was observed for immunocompromised
patients compared to 89% in non-neutropenic patients
(P = 0.007) [6]. In the latter group, fungal infection was
proven to be the main cause of death for 8 patients
(22.2%). Russo and colleagues [115] observed similar re-
sults: 14.3% of patients died as a direct consequence of
Aspergillus infection. The mortality rate in these patients
could be greater than in neutropenic patients. Compared
to neutropenic patients, non-neutropenic patients could
have a less symptomatic fungal infection with a compli-
cated diagnosis, leading to suboptimal management and
delayed therapy [6].
In a retrospective analysis of fungal infections in non-
neutropenic patients, Garbino and colleagues [116]
showed a mortality rate of 57.1% for patients with IA.
Trof and colleagues [11] showed that IA diagnosis was
established post-mortem in 38% of patients, 94% of
whom did not receive antifungal treatment. These data
could explain the results observed by Meersseman and
colleagues [16] in a restrospective cohort study on 127
ICU patients with IA; patients with proven or probable
infection without hematologic malignancy presented a
two-fold increase in mortality rate compared with mor-
tality expected by Simplified Acute Physiology Score II
score.
Prognostic factors have been examined in a variety of
studies. Isolation of Aspergillus in critically ill patients is
associated with high mortality, irrespective of invasion
or colonization [11]. Cornillet and colleagues [6] identi-
fied three factors associated with a poor prognosis: dis-
seminated infection (100% mortality rate), co-infection
(78% mortality rate) and bacterial pneumonia (78.5%
mortality rate). In conclusion, it is possible that the
overall mortality rate from IA is significantly higher in
non-neutropenic patients.
Conclusion
The management of IA in non-neutropenic, critically ill
patients represents a challenge for clinicians. Features of
IA in this cohort may contribute to a delay in diagnosis
and, consequently, to commencement of adequate anti-
fungal therapy. The complex underlying conditions and
the non-specificity of symptoms in non-neutropenic pa-
tients may be confounding and lead to underdiagnosis
and underestimates of the disease prevalence in
this population. Furthermore, current guidelines are
mainly designed for recognizing and managing IA in
hematological patients with severe and prolonged neu-
tropenia. Although recent advances in microbiological
techniques (GM analysis, PCR, and so on) showed
promising results in identifying IA also in non-
conventional subsets of patients, such as the critically ill,
a high level of suspicion of IA should be maintained
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use) are present. Voriconazole still represents the drug
of choice for IA in non-neutropenic patients. Since mortal-
ity resulting from IA in non-neutropenic, critically ill pa-
tients appears to be higher than in immunocompromised
patients and its management is problematic, studies on
large cohorts and trials to better define the characteristics
of IA are encouraged.
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